Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease ; volume:270 ; number:11 ; day:22 ; month:7 ; year:2023 ; pages:5461-5474 ; date:11.2023
Journal of neurology ; 270, Heft 11 (22.7.2023), 5461-5474, 11.2023
- Creator
-
Mizutani, Yasuaki
Ohdake, Reiko
Tatebe, Harutsugu
Higashi, Atsuhiro
Shima, Sayuri
Ueda, Akihiro
Ito, Mizuki
Tokuda, Takahiko
Watanabe, Hirohisa
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-023-11875-z
- URN
-
urn:nbn:de:101:1-2024010414042021708948
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mizutani, Yasuaki
- Ohdake, Reiko
- Tatebe, Harutsugu
- Higashi, Atsuhiro
- Shima, Sayuri
- Ueda, Akihiro
- Ito, Mizuki
- Tokuda, Takahiko
- Watanabe, Hirohisa
- SpringerLink (Online service)
Other Objects (12)
Application of Digital Cognitive Biomarkers for Alzheimer’s Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline
Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline
Awareness of Olfactory Dysfunction in Subjective Cognitive Decline, Mild Cognitive Decline, and Alzheimer’s Disease
Peripheral Leukocytosis Predicts Cognitive Decline but Not Behavioral Disturbances: A Nationwide Study of Alzheimer’s and Parkinson’s Disease Patients
Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression
Impaired 24-h activity patterns are associated with an increased risk of Alzheimer’s disease, Parkinson’s disease, and cognitive decline
Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Correction: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
Progressive cervical cord atrophy parallels cognitive decline in Alzheimer’s disease
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
Application of Digital Cognitive Biomarkers for Alzheimer’s Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline
Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline
Awareness of Olfactory Dysfunction in Subjective Cognitive Decline, Mild Cognitive Decline, and Alzheimer’s Disease
Peripheral Leukocytosis Predicts Cognitive Decline but Not Behavioral Disturbances: A Nationwide Study of Alzheimer’s and Parkinson’s Disease Patients
Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression
Impaired 24-h activity patterns are associated with an increased risk of Alzheimer’s disease, Parkinson’s disease, and cognitive decline
Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Correction: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
Progressive cervical cord atrophy parallels cognitive decline in Alzheimer’s disease
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
Application of Digital Cognitive Biomarkers for Alzheimer’s Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline
Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline
Awareness of Olfactory Dysfunction in Subjective Cognitive Decline, Mild Cognitive Decline, and Alzheimer’s Disease
Peripheral Leukocytosis Predicts Cognitive Decline but Not Behavioral Disturbances: A Nationwide Study of Alzheimer’s and Parkinson’s Disease Patients
Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression
Impaired 24-h activity patterns are associated with an increased risk of Alzheimer’s disease, Parkinson’s disease, and cognitive decline
Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Correction: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
Progressive cervical cord atrophy parallels cognitive decline in Alzheimer’s disease